Efficacy of Pregabalin Vs Duloxetine in Diabetic Peripheral Neuropathic Pain at Variable Dose
Status:
Not yet recruiting
Trial end date:
2022-10-01
Target enrollment:
Participant gender:
Summary
Background Diabetic neuropathy is a widespread, debilitating condition and its management
needs a significant cost. Around, 50% of diabetes mellitus (DM) patients suffer from Diabetic
Peripheral Neuropathic Pain (DPNP). According to the reported data, specific anticonvulsants
and antidepressants are effective for coping diabetic peripheral neuropathy. Two drugs,
duloxetine and pregabalin, are officially permitted by the Food and Drug Administration (FDA)
for the management of DPNP.
Methodology A Prospective Randomized Controlled Trial (RCT) trial for 12 weeks will be
carried out on 126 volunteer DPNP patients with age between 18- to 70-year-old and
participants was selected through consecutive sampling and will be evaluated on the basis of
duration of the disease, pain scales and the data provided by particular consultants. The
parameters will be measured weekly and final parameters will be measured after 12 weeks.
Statistical analysis will be carried out by SPSS, ANOVA, and t-test.
Expected outcomes:
From this experimental design, investigators are expecting improvement in the management of
DPNP and Duloxetine is more effective for treating patients suffering from DPNP.